Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer PatientsBusiness Wire • 07/09/25
TEM INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 07/09/25
Tempus Expands AI-Enabled Care Pathway Intelligence Platform into Breast CancerBusiness Wire • 07/08/25
Tempus AI Boosts R&D Efforts Through Wide-Ranging Product LaunchesZacks Investment Research • 07/07/25
Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 ReleaseZacks Investment Research • 07/04/25
TEM INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitPRNewsWire • 07/04/25
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. (TEM) Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewsWire • 07/02/25
Tempus Announces Pricing of Upsized Offering of $650 Million of Convertible Senior NotesBusiness Wire • 07/01/25
INVESTOR NOTICE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEMPRNewsWire • 06/28/25
TEM Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Against TEMGlobeNewsWire • 06/27/25
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?Zacks Investment Research • 06/27/25
Tempus AI, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. December 16, 2024 Deadline to file Lead Plaintiff Motion.GlobeNewsWire • 06/26/25
Deadline Approaching: Tempus AI, Inc. (TEM) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire • 06/26/25
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – TEMGlobeNewsWire • 06/26/25
Ambry Genetics' CARE Program Validated for Accuracy in Identifying High-Risk Patients for Hereditary Cancer TestingBusiness Wire • 06/25/25
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • 06/24/25
Law Offices of Howard G. Smith Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • 06/24/25
TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?Zacks Investment Research • 06/23/25
Law Offices of Frank R. Cruz Encourages Tempus AI, Inc. (TEM) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • 06/23/25